Pigmented skin lesions with atypical histopathology indicating a diagnosis of multiple metastases of melanoma: A case report

He,Yun; Fan,Huanfang; Du,Zhihua; Li,Dehui; Gu,Yiting; Liu,Zihui

doi:10.3892/ol.2025.15115

Pigmented skin lesions with atypical histopathology indicating a diagnosis of multiple metastases of melanoma: A case report

Authors:
- Yun He
- Huanfang Fan
- Zhihua Du
- Dehui Li
- Yiting Gu
- Zihui Liu
View Affiliations

Affiliations: The Graduate School, Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050011, P.R. China, Second Department of Oncology, The First Affiliated Hospital of Hebei University of Chinese Medicine, Shijiazhuang, Hebei 050011, P.R. China
Published online on: May 27, 2025 https://doi.org/10.3892/ol.2025.15115
Article Number: 369
Copyright: © He et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The present study reports on the case of a middle‑aged female patient who presented with a rapidly progressing pigmented skin lesion on the periphery, combined with multiple intracranial, pulmonary, hepatic and skeletal malignancies. The case was not clear in terms of histopathological manifestations and other aspects, which made the diagnosis of melanoma difficult. The present case details the challenges in the diagnostic process, as well as the importance of multidisciplinary comprehensive diagnosis and treatment, aiming to provide a reference for clinicians when dealing with similar complex pigmented skin lesions.

View Figures

View References

1	WU Na-Ming, LI Jun and TAO Juan: Diagnostic hotspots of malignant melanoma. Diagn Theory Pract (Chinese). 2:215–220. 2023.
2	Wang JY, Wang EB and Swetter SM: What is melanoma? JAMA. 329:9482023. View Article : Google Scholar : PubMed/NCBI
3	Haydu LE, Lo SN, McQuade JL, Amaria RN, Wargo J, Ross MI, Cormier JN, Lucci A, Lee JE, Ferguson SD, et al: Cumulative incidence and predictors of CNS metastasis for patients with American joint committee on cancer 8th edition stage iii melanoma. J Clin Oncol. 38:1429–1441. 2020. View Article : Google Scholar : PubMed/NCBI
4	National Comprehensive Cancer Network, . NCCN Guidelines for Ovarian Cancer. NCCN; Philadelphia: 2025
5	Etchevers HC: Hiding in plain sight: Molecular genetics applied to giant congenital melanocytic nevi. J Invest Dermatol. 134:879–882. 2014. View Article : Google Scholar : PubMed/NCBI
6	Gerami P and Paller AS: Making a mountain out of a molehill: NRAS, mosaicism, and large congenital nevi. J Invest Dermatol. 133:2127–2130. 2013. View Article : Google Scholar : PubMed/NCBI
7	National Comprehensive Cancer Network, . NCCN Guidelines for Melanoma. NCCN; Philadelphia: 2025
8	Gessi M, Hammes J, Lauriola L, Dörner E, Kirfel J, Kristiansen G, Zur Muehlen A, Denkhaus D, Waha A and Pietsch T: GNA11 and N-RAS mutations: Alternatives for MAPK pathway activating GNAQ mutations in primary melanocytic tumours of the central nervous system. Neuropathol Appl Neurobiol. 4:417–425. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chen HC, Hsu TI, Chao TY and Yang ST: Neurocutaneous melanosis with meningeal melanocytosis: A rare case of intracranial hypertension and cutaneous manifestations. Life (Basel). 14:1392024.PubMed/NCBI
10	Kinsler VA, Thomas AC, Ishida M, Bulstrode NW, Loughlin S, Hing S, Chalker J, McKenzie K, Abu-Amero S, Sater O, et al: Multiple congenital melanocytic nevi and neurocutaneous melanosis are caused by postzygotic mutations in codon 61 of NRAS. J Invest Dermatol. 9:2229–2236. 2013. View Article : Google Scholar : PubMed/NCBI
11	Jakchairoongruang K, Khakoo Y, Beckwith M and Barkovich AJ: New insights into neurocutaneous melanosis. Pediatr Radiol. 48:1786–1796. 2018. View Article : Google Scholar : PubMed/NCBI
12	Vanood A, Lee YA, Leleszi E and Krishnan A: Symptomatic neurocutaneous melanosis: Mild clinical onset in a teenager. BMJ Case Rep. 13:e2357722020. View Article : Google Scholar : PubMed/NCBI
13	Gerami P, Kim D, Zhang B, Compres EV, Khan AU, Yazdan P, Guitart J and Busam K: Desmoplastic melanomas mimicking neurofibromas. Am J Dermatopathol. 42:916–922. 2020. View Article : Google Scholar : PubMed/NCBI
14	Kashani-Sabet M: Molecular markers in melanoma. Br J Dermatol. 170:31–35. 2014. View Article : Google Scholar : PubMed/NCBI
15	Lee BM and Yang YG: Interpretation of the European expert consensus-based multidisciplinary melanoma diagnosis and treatment guideline 2022 edition. J Prac Dermatol (Chinese). 16:153–155. 2023.
16	Várvölgyi T, Janka EA, Szász I, Koroknai V, Toka-Farkas T, Szabó IL, Ványai B, Szegedi A, Emri G and Balázs M: Combining biomarkers for the diagnosis of metastatic melanoma. J Clin Med. 13:1742023. View Article : Google Scholar : PubMed/NCBI
17	Janka EA, Várvölgyi T, Sipos Z, Soós A, Hegyi P, Kiss S, Dembrovszky F, Csupor D, Kéringer P, Pécsi D, et al: Predictive performance of serum S100B versus LDH in melanoma patients: A systematic review and meta-analysis. Front Oncol. 11:7721652021. View Article : Google Scholar : PubMed/NCBI
18	Doolan BJ, Robinson AJ, Wolfe R, Kelly JW, McLean C, McCormack C, Henderson MA and Pan Y: Accuracy of partial biopsies in the management of cutaneous melanoma. Australas J Dermatol. 60:209–213. 2019. View Article : Google Scholar : PubMed/NCBI
19	Randic T, Kozar I, Margue C, Utikal J and Kreis S: NRAS mutant melanoma: Towards better therapies. Cancer Treat Rev. 99:1022382021. View Article : Google Scholar : PubMed/NCBI
20	Valpione S and Campana LG: Immunotherapy for advanced melanoma: Future directions. Immunotherapy. 8:199–209. 2016. View Article : Google Scholar : PubMed/NCBI
21	Klobuch S, Seijkens TTP, Schumacher TN and Haanen JBAG: Tumour-infiltrating lymphocyte therapy for patients with advanced-stage melanoma. Nat Rev Clin Oncol. 21:173–184. 2024. View Article : Google Scholar : PubMed/NCBI
22	Russo V, Lunghi F, Fontana R and Bregni M: A clinical study of a cell-based MAGE-A3 active immunotherapy in advanced melanoma patients. J Cancer. 2:329–330. 2011. View Article : Google Scholar : PubMed/NCBI
23	Lu C and Tan Y: Promising immunotherapy targets: TIM3, LAG3, and TIGIT joined the party. Mol Ther Oncol. 32:2007732024. View Article : Google Scholar : PubMed/NCBI
24	Ascierto PA, Agarwala SS, Blank C, Caracò C, Carvajal RD, Ernstoff MS, Ferrone S, Fox BA, Gajewski TF, Garbe C, et al: Perspectives in melanoma: Meeting report from the melanoma bridge (December 2nd-4th, 2021, Italy). J Transl Med. 20:3912022. View Article : Google Scholar : PubMed/NCBI
25	Ma B, Akosman B, Kamle S, Lee CM, He CH, Koo JS, Lee CG and Elias JA: CHI3L1 regulates PD-L1 and anti-CHI3L1-PD-1 antibody elicits synergistic antitumor responses. J Clin Invest. 131:e1377502021. View Article : Google Scholar : PubMed/NCBI
26	Shah PD, Huang AC, Xu X, Orlowski R, Amaravadi RK, Schuchter LM, Zhang P, Tchou J, Matlawski T, Cervini A, et al: Phase I trial of autologous RNA-electroporated cMET-directed CAR T cells administered intravenously in patients with melanoma and breast carcinoma. Cancer Res Commun. 3:821–829. 2023. View Article : Google Scholar : PubMed/NCBI
27	Hibler W, Merlino G and Yu Y: CAR NK cell therapy for the treatment of metastatic melanoma: Potential & prospects. Cells. 12:27502023. View Article : Google Scholar : PubMed/NCBI
28	Cui C, Wang X, Lian B, Ji Q, Zhou L, Chi Z, Si L, Sheng X, Kong Y, Yu J, et al: OrienX010, an oncolytic virus, in patients with unresectable stage IIIC-IV melanoma: A phase Ib study. J Immunother Cancer. 10:e0043072022. View Article : Google Scholar : PubMed/NCBI